2-chloro-5-methylisonicotinonitrile | 1261685-10-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-chloro-5-methylisonicotinonitrile
• 英文别名: 2-Chloro-5-methylpyridine-4-carbonitrile；2-chloro-5-methylpyridine-4-carbonitrile
• CAS: 1261685-10-2
• 化学式: C₇H₅ClN₂
• 分子量: 152.583
• InChiKey: LKKHBZMDFNANDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-甲基-4-氰基吡啶 在 间氯过氧苯甲酸 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 19.0h， 生成 2-chloro-5-methylisonicotinonitrile
  参考文献：
  名称：

  [EN] SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS
  [FR] DÉRIVÉS HÉTÉROCYCLIQUES BICYCLIQUES SUBSTITUÉS UTILES EN TANT QU'INHIBITEURS DE CANAL ROMK

  摘要：

  公开号：

  WO2018093569A4

文献信息

• [EN] D-AMINO ACID OXIDASE ACTIVITY INHIBITING COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE L'ACTIVITÉ DE D-AMINO ACIDE OXYDASE
  申请人：RICHTER GEDEON NYRT

  公开号：WO2019043635A1

  公开（公告）日：2019-03-07

  Compounds of formula (I), wherein R1 through R3 are as defined in the claims, or pharmaceutically acceptable esters, salts, hydrates or solvates thereof, useful as DAAO inhibitors as well as pharmaceutical compositions containing them and their use as modulators of DAAO activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject are provided.

  式(I)的化合物，其中R1至R3如权利要求中所定义，或其药用可接受的酯、盐、水合物或溶剂化合物，可用作DAAO抑制剂，以及含有它们的药物组合物以及它们作为DAAO活性调节剂、D-丝氨酸水平、D-丝氨酸氧化产物和NMDA受体活性在哺乳动物主体的神经系统中的使用。
• Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10723723B2

  公开（公告）日：2020-07-28

  Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is (II) or (III); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

  公开了式(I)化合物或其盐，其中R1是(II)或(III)；每个W独立地是NR1b或O；Z是键或CHR1d；R1、R2、Rd、R3、L1、L2、R1a、R1b、R1c和n在此定义。还公开了使用此类化合物作为 ROMK 抑制剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗心血管疾病。
• SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3535258A1

  公开（公告）日：2019-09-11
• SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3535258B1

  公开（公告）日：2021-11-24
• 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS
  申请人：Kim Ronald M.

  公开号：US20170320874A1

  公开（公告）日：2017-11-09

  The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.